title: [Crizotinib for ROS1-rearranged non-small cell lung cancer patients].
abstract: ROS1 fusions are rare mutations that preferentially concern young and non-smoker women. The ROS1-rearranged protein conserves an intact tyrosine kinase domain, leading to the constitutive activation of the ROS1 tyrosine kinase function and of its downstream pathways, that are known to be involved in tumorigenesis. These molecular abnormalities have shown their oncogenic potential in animals' models and in human, with an early effect on carcinogenesis. Several partners have been identified. Patients with non-small cell lung cancers (NSCLC) harbouring ROS1 alterations can receive specific targeted therapies. Indeed, crizotinib has recently been approved in France in advanced ROS1-rearranged NSCLC. We propose a review of the oncogenic role of ROS1 rearrangements, the different methods for its diagnosis, and the available treatments.
authors.affiliation: GH HUEP, AP-HP, hôpital Tenon, service de pneumologie, 4, rue de la Chine, 75970 Paris, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Domblides
authors.affiliation: Hôpital Tenon, Sorbonne universités, UPMC université Paris 06, Theranoscan, GRC n(o) 04, 4, rue de la Chine, 75252 Paris, France; Hôpital Tenon, AP-HP, GH HUEP, service d'anatomie pathologique, 75970 Paris, France.
authors.forename: Martine
authors.initials: M
authors.lastname: Antoine
authors.affiliation: GH HUEP, AP-HP, hôpital Tenon, service de pneumologie, 4, rue de la Chine, 75970 Paris, France.
authors.forename: Armelle
authors.initials: A
authors.lastname: Lavole
authors.affiliation: GH HUEP, AP-HP, hôpital Tenon, service de pneumologie, 4, rue de la Chine, 75970 Paris, France; Hôpital Tenon, Sorbonne universités, UPMC université Paris 06, Theranoscan, GRC n(o) 04, 4, rue de la Chine, 75252 Paris, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
authors.affiliation: GH HUEP, AP-HP, hôpital Tenon, service de pneumologie, 4, rue de la Chine, 75970 Paris, France; Hôpital Tenon, Sorbonne universités, UPMC université Paris 06, Theranoscan, GRC n(o) 04, 4, rue de la Chine, 75252 Paris, France. Electronic address: marie.wislez@aphp.fr.
authors.forename: Marie
authors.initials: M
authors.lastname: Wislez
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D002986:Clinical Trials as Topic; D000077547:Crizotinib; D017277:Drug Approval; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D015321:Gene Rearrangement; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D058990:Molecular Targeted Therapy / Q000379:methods; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000235:genetics* / Q000502:physiology; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000502:physiology; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D015398:Signal Transduction
chemical_list: D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D011505:Protein-Tyrosine Kinases; C062333:ROS1 protein, human
keywords: Cancer bronchique non à petites cellules; Crizotinib; Non-small cell lung cancer; ROS1-positive; Réarrangement de ROS1